Acute Kidney Injuries Market
Number of pages: 100 | Report Format: PDF | Published date: May 25, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.57 billion |
|
Revenue Forecast in 2031 |
US$ 3.01 billion |
|
CAGR |
7.45% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type of injuries, Treatment, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global acute kidney injuries market was valued at US$ 1.57 billion in 2022 and is expected to register a revenue CAGR of 7.45% to reach US$ 3.01 billion by 2031.
Acute Kidney Injuries Market Fundamentals
Acute kidney injury (AKI) is a condition characterized by the rapid loss of kidney function that typically occurs over a period of hours or days. This is marked by decreased urine output and increased serum creatinine levels. Different factors like dehydration, sepsis, medication toxicity, or pre-existing health conditions like diabetes or heart failure can cause acute kidney injury. AKI can occur within hours to days, potentially reversible if diagnosed and managed promptly. Preventive measures for AKI include maintaining adequate hydration, avoiding nephrotoxic medications when possible, managing chronic medical conditions effectively, and closely monitoring patients at high risk for AKI during hospitalization. The management of AKI focuses on treating the underlying cause, providing supportive care, and preventing complications.
Over the past few years, many developments have been in managing and treating acute kidney injury. A significant trend is the implementation of precision medicine strategies that use genetic and biomarker information to customize treatment plans for each patient. This personalized approach enables healthcare professionals to identify patients who are at a higher risk of acute kidney injury and take preventive measures accordingly. Additionally, specific patient characteristics are considered to optimize therapies.
Industry players have adopted various strategies to generate high revenue and meet the increasing demand for acute kidney injury management solutions. They focus on creating and introducing innovative diagnostic tests and monitoring devices to detect AKI early and provide real-time monitoring. These advanced technologies provide healthcare providers valuable tools to quickly identify AKI cases, enabling timely intervention and improved patient care.
Furthermore, market players are investing in research and development to explore new treatment modalities for acute kidney injury. This includes the development of targeted therapies and novel pharmaceutical agents that aim to prevent or mitigate the damage caused by AKI. By expanding their product portfolios to include innovative treatments, market players can tap into the evolving landscape of AKI management, cater to unmet medical needs, and ultimately drive revenue growth.
-Market_1685008659.jpg)
Acute Kidney Injuries Market Dynamics
Acute Kidney Injury (AKI) is a frequent occurrence among hospitalized patients. In the United States, 1% of all hospital admissions involve AKI. It can play a significant role in admitting patients for other conditions, and sometimes it is the primary reason for hospitalization. Additionally, AKI develops in about 2% to 5% of patients while hospitalized and is observed in up to 67% of patients in intensive care units. AKI is often caused by decreased kidney blood flow, especially in individuals with pre-existing health issues. This decrease in blood flow may be due to factors such as low blood volume following bleeding, excessive vomiting or diarrhea, or severe dehydration.
Additionally, recent research and development have resulted in the development of several targeted pharmaceuticals for treating acute kidney injuries. For instance, HO-1, or Heme Oxygenase 1, is a valuable enzyme that provides antioxidant benefits by quickly breaking down free heme and producing protective by-products like carbon monoxide, bilirubin, and ferritin. It aids in reducing inflammation during acute kidney injuries by regulating immune cell gene expression, maturation, and migration. In addition, HO-1 is a powerful regulator of autophagy and helps prevent cell death by reducing p21 activity. Studies have demonstrated that HO-1 induction can help protect against cisplatin and ischemia-reperfusion renal injury models.
Despite its growth potential, the global acute kidney injuries market is subject to certain restraining factors that can impact its revenue growth and expansion. The treatment of acute kidney injuries is expensive, especially in cases where dialysis and other renal replacement therapies are required. The financial burden associated with acute kidney injury treatment can limit access to appropriate care, particularly in resource-constrained healthcare settings. Affordable and cost-effective treatment options are needed to ensure wider access to AKI management.
Acute Kidney Injuries Market Ecosystem
The global acute kidney injuries market is analyzed from four perspectives: type of injuries, treatment, and region.
Acute Kidney Injuries Market by Type of Injuries
Based on the type of injuries, the global acute kidney injuries market is segmented into pre-renal acute kidney injury, intrinsic renal acute kidney injuries, and post-renal acute kidney injuries.
The pre-renal acute kidney injuries segment accounted for 62% of the acute kidney injuries market share in 2022. This is majorly attributed to the presence of a large patient pool. According to the National Center for Biotechnology Information, pre-renal acute kidney injuries have 55% of total acute kidney injury cases. Moreover, the increasing admissions of patients in the intensive care unit also support the growth of the pre-renal acute kidney injuries segment. In 2022, the eClinical Medicine journal stated that acute kidney injuries frequently occur in critical disorders. The incidence of acute kidney injuries in the intensive care unit (ICU) literature has been reported to range from 30-57%.
The intrinsic renal acute kidney injuries segment is expected to increase in the forecast years. This is because intrinsic renal acute kidney injuries have 45% of all acute kidney injury cases, states National Center for Biotechnology Information. In addition, many pipeline drugs to treat acute kidney injuries are expected to increase the revenue share of the intrinsic renal acute kidney injuries segment in the forecast years.
Acute Kidney Injuries Market by Treatment
Based on treatment, the global acute kidney injuries market is segmented into drug therapy and dialysis.
The dialysis segment accounted for the majority of revenue share in the global acute kidney injuries market. This is majorly attributed to the effectiveness of dialysis in managing acute kidney injuries. Additionally, the preference for dialysis is also increasing due to rising technological advancements in dialysis equipment and procedures, further fueling the revenue growth of the dialysis segment.
It is anticipated that the increasing availability of dialysis will increase the demand for its use in treating acute kidney injuries. The United States Renal Data System (USRDS) reported that over 7,500 dialysis centers are present in the U.S. in 2021.
Acute Kidney Injuries Market by Region
Based on the region, the acute kidney injuries market is segmented into North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa.
The North America acute kidney injuries market accounted for 44% revenue share in 2022. This is mainly attributed to the high prevalence of chronic kidney diseases and the availability of advanced healthcare infrastructure. The increasing adoption of dialysis and renal replacement therapies in the region has also contributed to the market’s growth. In addition, the rising geriatric population, and the risk of developing acute kidney injuries, further drive the demand for effective treatment options.
The Asia Pacific acute kidney injuries market is projected to show a significant growth of 8.2% CAGR in the forecast years. The Asia Pacific region has experienced a rise in the incidence of AKI, primarily due to factors such as an aging population, increasing prevalence of chronic diseases (e.g., diabetes, hypertension), and higher rates of sepsis and other conditions that can lead to kidney injury. The region has experienced substantial economic growth and improved healthcare infrastructure, particularly in countries such as China, India, and Japan. This has resulted in enhanced access to healthcare services, including early detection, diagnosis, and treatment of acute kidney injuries. There has also been a growing awareness among healthcare professionals and patient about the importance of early detection and diagnosis of AKI. This has led to improved screening practices, implementation of AKI clinical guidelines, and enhanced diagnostic tools to identify AKI cases promptly.
Some of the prominent companies having the largest revenue share in the global Acute Kidney Injuries Market are,
Strategic Developments
AKI, or acute kidney injury, is a condition characterized by the rapid loss of kidney function that typically occurs over a period of hours or days.
The global acute kidney injuries market is expected to reach US$ 3.01 billion by 2031.
The global acute kidney injuries market has witnessed significant growth in recent years due to the increasing prevalence of acute kidney injury in ICU patients and increased accessibility of dialysis.
The global acute kidney injuries market is expected to register a revenue CAGR of 7.45% in the forecast period from 2023 to 2031.
North America region has dominated the global acute kidney injuries market.
*Insights on financial performance are subject to the availability of information in the public domain